A bender includes a rotatable bending shoe having at least one channel therein configured to receive a workpiece, a seat proximate to the bending shoe which is configured to receive the workpiece thereon, and a sensor provided on the seat which is configured to sense the presence of the workpiece. In some embodiments, the sensor is configured to sense an end of the workpiece.

The present invention relates to a method of treating neuropathy by administering DNA constructs, encoding a human IGF-1 isoform and a human HGF isoform. Further provided herein are various DNA constructs and pharmaceutical compositions including the DNA constructs that can be used for the combination therapy. The present invention provides a safe and effective way of treating neuropathic patients.

One disadvantage of adeno-associated virus (AAV) is low gene expression efficiency due to delayed expression of the inserted gene. Provided is a vector plasmid for producing a vector genome to be inserted into an adeno-associated virus (AAV). The vector plasmid is provided with a vector genome cassette as a template of the vector genome, and the vector genome cassette is provided with: (1) an expression cassette including a nucleic acid molecule encoding a target gene and (b) a nucleic acid molecule encoding an expression regulatory region that allows expression of the target gene; and (2) two nucleic acid molecules positioned on both sides of the expression cassette and encoding inverted terminal repeats (ITRs). Also provided is a pharmaceutical composition containing the AVV vector, for treating or preventing an eye disease or disease associated with same. Further provided is a method for treating or preventing the eye disease or disease associated with same, comprising administering a therapeutically effective amount of the pharmaceutical composition for treating or preventing the eye disease or disease associated with same to a subject suffering from the eye disease or disease associated with same.

The present invention relates to a pharmaceutical composition for the prevention or treatment of diabetic neuropathy, wherein the pharmaceutical composition comprises, as active ingredients, different types of isoforms of HGF or a polynucleotide encoding the isoforms. The present invention is the first invention demonstrating that diabetic neuropathy can be prevented and treated using different types of isoforms of HGF. According to the present invention, it is possible to very effectively treat diabetic neuropathy.

The present invention relates to cell lines that are genetically modified to overexpress a -galactoside -2,3-sialyltransferase 1 (ST3Gal1), preferably human ST3Gal1, which can be used for the production of recombinant glycoproteins having highly or fully sialylated O-linked GalNAc glycans (GalNAc O-glycans), preferably core 1 GalNAc O-glycans, as well as to respective recombinant glycoproteins. Further, the present invention relates to respective methods of expressing recombinant glycoproteins, methods of increasing the degree of sialylation of recombinant glycoproteins, and methods of decreasing the micro-heterogeneity of GalNAc O-glycans. Finally, the present invention relates to respective uses of the above cell lines for the production of recombinant glycoproteins, for increasing the degree of sialylation of recombinant glycoproteins, and for decreasing the micro-heterogeneity of O-linked GalNAc glycans of recombinant glycoproteins.

A bender includes a rotatable bending shoe having a plurality of channels therein configured to receive a workpiece and a follower assembly. The follower assembly includes a mount, a follower bar attached to the mount, the follower bar having a plurality of channels therein configured to receive the workpiece, a roller attached to the mount and engaged against the follower bar, the roller having an eccentric shaft extending therefrom, and a motor for rotating the shaft and roller, wherein rotation of the shaft and roller causes the follower bar to translate toward or away from the bending shoe. A drive member can be provided to move the mount toward or away from the bending shoe.

The present invention relates to a pharmaceutical composition for the prevention or treatment of diabetic neuropathy, wherein the pharmaceutical composition comprises, as active ingredients, different types of isoforms of HGF or a polynucleotide encoding the isoforms. The present invention is the first invention demonstrating that diabetic neuropathy can be prevented and treated using different types of isoforms of HGF. According to the present invention, it is possible to very effectively treat diabetic neuropathy.

The present invention provides a method of inhibiting progression of or preventing renal disorder, the method comprising applying a cell sheet composition for inhibiting progression of or preventing renal disorder to at least one part of the surface of a kidney, wherein the part of the surface is uncovered by a fibrous capsule of the kidney. The present invention also provides a cell sheet composition for inhibiting progression of or preventing renal disorder, the cell sheet composition comprising a cell that has a function of producing a hepatocyte growth factor (HGF). The present invention also provides a method of producing a cell sheet composition for inhibiting progression of or preventing renal disorder.

The purpose of the present invention is to provide a therapeutic agent for dilated cardiomyopathy disease which produces excellent effects in the treatment of dilated cardiomyopathy (DCM) and provides a given benefit to a large number of patients. The present invention is a therapeutic agent for dilated cardiomyopathy comprising at least one selected from the group consisting of mesenchymal stem cell and microparticles derived from the mesenchymal stem cell. It is preferable that the mesenchymal stem cell is a cell having the ability to contain or secrete microparticles, that the microparticles have an average particle size of 1000 nm or less, and that they are exosomes.

The present invention relates to a composition for preventing or treating amyotrophic lateral sclerosis, the composition containing, as an active ingredient, two or more isoforms of a hepatocyte growth factor (HGF) or a polynucleotide encoding the isoforms. The composition of the present invention is used to effectively prevent or treat amyotrophic lateral sclerosis.